Skip to main content

Advertisement

Table 1 Patient characteristics at baseline, Full Analysis Set

From: Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies

  Monotherapy Study Combination Therapy Study
Dulaglutide
0.75 mg
(N = 280)
Liraglutide
0.9 mg
(N = 137)
Placebo
(N = 70)
Dulaglutide
0.75 mg
(N = 181)
Insulin
Glargine
(N = 180)
Females, n (%) 52 (19%) 24 (18%) 15 (21%) 56 (31%) 47 (26%)
Age (yrs), mean (SD) 57.2 (9.6) 57.9 (10.4) 57.7 (8.3) 57.5 (10.5) 56.1 (11.3)
Weight (kg), mean (SD) 71.3 (12.5) 70.2 (12.5) 69.3 (11.6) 70.9 (13.7) 71.1 (13.8)
BMI (kg/m2), mean (SD) 25.6 (3.6) 25.5 (3.5) 25.2 (3.2) 26.1 (3.6) 25.9 (3.9)
Diabetes duration (yrs), mean (SD) 6.8 (5.6) 6.3 (6.0) 6.3 (5.1) 8.9 (6.7) 8.8 (6.1)
HbA1c (%), mean (SD) 8.2 (0.8) 8.1 (0.9) 8.2 (0.8) 8.1 (0.8) 8.0 (0.9)
Receiving OHA at screening, n (%) 94 (34%) 48 (35%) 22 (31%) 181 (100%) 180 (100%)
OHA-naive, n (%) 186 (66%) 89 (65%) 48 (69%) 0 (0%) 0 (0%)
Concomitant OHA at baseline, n (%)
 Sulfonylureas only NA NA NA 34 (19%) 33 (18%)
 Biguanides only NA NA NA 64 (35%) 66 (37%)
 Sulfonylureas and biguanides NA NA NA 83 (46%) 81 (45%)
EQ-5D-5L Japan Index, mean (SD) 0.97 (0.06) 0.97 (0.06) 0.96 (0.08) NA NA
EQ-5D VAS, mean (SD) 82.6 (12.7) 81.0 (11.4) 79.3 (14.2) NA NA
  1. BMI Body mass index, HbA1c Glycosylated hemoglobin A1c, NA Not applicable, OHA Oral hypoglycemic agent, SD Standard deviation, VAS Visual analog scale